Matinas BioPharma Holdings, Inc. (MTNB)
1.701
-0.01
(-0.55%)
USD |
NYAM |
Oct 23, 16:00
1.71
+0.01
(+0.55%)
After-Hours: 20:00
Matinas BioPharma Holdings Enterprise Value : -0.0787M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -0.0787M |
| October 22, 2026 | -0.0747M |
| October 21, 2026 | -0.1558M |
| October 20, 2026 | -0.0789M |
| October 19, 2026 | -0.096M |
| October 16, 2026 | 0.2072M |
| October 15, 2026 | 0.2286M |
| October 14, 2026 | 0.2542M |
| October 13, 2026 | 0.2627M |
| October 12, 2026 | 0.3653M |
| October 09, 2026 | 0.4208M |
| October 08, 2026 | 0.4037M |
| October 07, 2026 | 0.3781M |
| October 06, 2026 | 0.4806M |
| October 05, 2026 | 0.3994M |
| October 02, 2026 | 0.3225M |
| October 01, 2026 | 0.2286M |
| September 30, 2026 | 0.2841M |
| September 29, 2026 | 0.425M |
| September 28, 2026 | 0.2756M |
| September 25, 2026 | 0.22M |
| September 24, 2026 | 0.3354M |
| September 23, 2026 | 0.3161M |
| September 22, 2026 | 0.3289M |
| September 21, 2026 | 0.3091M |
| Date | Value |
|---|---|
| September 18, 2026 | 0.2226M |
| September 17, 2026 | 0.2393M |
| September 16, 2026 | 0.2527M |
| September 15, 2026 | 0.22M |
| September 14, 2026 | 0.425M |
| September 11, 2026 | 0.3802M |
| September 10, 2026 | 0.5083M |
| September 09, 2026 | 0.3719M |
| September 08, 2026 | 0.361M |
| September 04, 2026 | 0.361M |
| September 03, 2026 | 0.3546M |
| September 02, 2026 | 0.3866M |
| September 01, 2026 | 0.4616M |
| August 31, 2026 | 0.4616M |
| August 28, 2026 | 0.4763M |
| August 27, 2026 | 0.4763M |
| August 26, 2026 | 0.4532M |
| August 25, 2026 | 0.459M |
| August 24, 2026 | 0.4539M |
| August 21, 2026 | 0.4686M |
| August 20, 2026 | 0.3642M |
| August 19, 2026 | 0.739M |
| August 18, 2026 | 0.50M |
| August 17, 2026 | 0.6185M |
| August 14, 2026 | 0.6941M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.326M |
| Total Expenses (Quarterly) | 1.326M |
| EPS Diluted (Quarterly) | -3.105 |
| Earnings Yield | -1.06K% |
| Normalized Earnings Yield | -1094.65 |